Gilead's Trodelvy Broad FDA Approval in Front-Line TNBC Fuels TROP2 ADC Market War on June 25, 2026 First line treatment Gilead Sciences locally advanced metastatic triple-negative breast cancer mTNBC pembrolizumab sacituzumab govitecan-hziy Trodelvy United States Food and Drug Administration Unresectable +
Trodelvy misses lung cancer endpoint, but Gilead and Merck score HIV win with weekly combo on June 09, 2026 EVOKE-03 trial Gilead Merck HIV islatravir Keytruda combo Lenacapavir Malignant neoplasm of lung once-weekly Success Trodelvy +
Gilead Cell Therapy Sales Drop 11% in Q3 2025, HIV Franchise Drives Growth on November 01, 2025 Biktarvy cell therapy sales financial results Gilead Sciences HIV franchise Livdelzi Q3 Tecartus Trodelvy Veklury Yescarta Yeztugo +
Gilead Bolsters Trodelvy in Triple-Negative Breast Cancer With Practice-Changing Keytruda Combo Win on June 04, 2025 Antibody-Drug Conjugates Combined Modality Therapy Gilead Sciences Immunotherapy Keytruda Phase 3 Trial practice-changing Progression-Free Survival TNBC Triple Negative Breast Neoplasms Trodelvy +
Gilead eyes earlier use of Trodelvy in TNBC as Phase III hits key goal on April 22, 2025 Keytruda Metastatic to Overall Survival Triple Negative Breast Neoplasms Trodelvy +